[Pharmacogenomics of multiple sclerosis

association of immune response genes polymorphism with copaxone treatment efficacy].

E. I. Tsareva, O. G. Kulakova, O. I. Makarycheva, A. N. Boǐko, S. G. Shchur, N. I. Lashch, N. F. Popova, E. I. Gusev, V. V. Bashinskaia, D. V. L'vov, Alexander Favorov, M. F. Ochs, O. O. Favorova

Research output: Contribution to journalArticle

Abstract

Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)963-972
Number of pages10
JournalMolekuliarnaia biologiia
Volume45
Issue number6
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Pharmacogenetics
Interleukin-7 Receptor alpha Subunit
Multiple Sclerosis
Interferon alpha-beta Receptor
CCR5 Receptors
CTLA-4 Antigen
Transforming Growth Factor beta1
Genes
Tumor Necrosis Factor-alpha
Histocompatibility
HLA Antigens
Immunotherapy
Therapeutics
Alleles
Glatiramer Acetate

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Tsareva, E. I., Kulakova, O. G., Makarycheva, O. I., Boǐko, A. N., Shchur, S. G., Lashch, N. I., ... Favorova, O. O. (2011). [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy]. Molekuliarnaia biologiia, 45(6), 963-972.

[Pharmacogenomics of multiple sclerosis : association of immune response genes polymorphism with copaxone treatment efficacy]. / Tsareva, E. I.; Kulakova, O. G.; Makarycheva, O. I.; Boǐko, A. N.; Shchur, S. G.; Lashch, N. I.; Popova, N. F.; Gusev, E. I.; Bashinskaia, V. V.; L'vov, D. V.; Favorov, Alexander; Ochs, M. F.; Favorova, O. O.

In: Molekuliarnaia biologiia, Vol. 45, No. 6, 11.2011, p. 963-972.

Research output: Contribution to journalArticle

Tsareva, EI, Kulakova, OG, Makarycheva, OI, Boǐko, AN, Shchur, SG, Lashch, NI, Popova, NF, Gusev, EI, Bashinskaia, VV, L'vov, DV, Favorov, A, Ochs, MF & Favorova, OO 2011, '[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].', Molekuliarnaia biologiia, vol. 45, no. 6, pp. 963-972.
Tsareva EI, Kulakova OG, Makarycheva OI, Boǐko AN, Shchur SG, Lashch NI et al. [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy]. Molekuliarnaia biologiia. 2011 Nov;45(6):963-972.
Tsareva, E. I. ; Kulakova, O. G. ; Makarycheva, O. I. ; Boǐko, A. N. ; Shchur, S. G. ; Lashch, N. I. ; Popova, N. F. ; Gusev, E. I. ; Bashinskaia, V. V. ; L'vov, D. V. ; Favorov, Alexander ; Ochs, M. F. ; Favorova, O. O. / [Pharmacogenomics of multiple sclerosis : association of immune response genes polymorphism with copaxone treatment efficacy]. In: Molekuliarnaia biologiia. 2011 ; Vol. 45, No. 6. pp. 963-972.
@article{a795173d3053407986f473285400c4e4,
title = "[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].",
abstract = "Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.",
author = "Tsareva, {E. I.} and Kulakova, {O. G.} and Makarycheva, {O. I.} and Boǐko, {A. N.} and Shchur, {S. G.} and Lashch, {N. I.} and Popova, {N. F.} and Gusev, {E. I.} and Bashinskaia, {V. V.} and L'vov, {D. V.} and Alexander Favorov and Ochs, {M. F.} and Favorova, {O. O.}",
year = "2011",
month = "11",
language = "English (US)",
volume = "45",
pages = "963--972",
journal = "Molekulyarnaya Biologiya",
issn = "0026-8984",
publisher = "Russian Academy of Sciences",
number = "6",

}

TY - JOUR

T1 - [Pharmacogenomics of multiple sclerosis

T2 - association of immune response genes polymorphism with copaxone treatment efficacy].

AU - Tsareva, E. I.

AU - Kulakova, O. G.

AU - Makarycheva, O. I.

AU - Boǐko, A. N.

AU - Shchur, S. G.

AU - Lashch, N. I.

AU - Popova, N. F.

AU - Gusev, E. I.

AU - Bashinskaia, V. V.

AU - L'vov, D. V.

AU - Favorov, Alexander

AU - Ochs, M. F.

AU - Favorova, O. O.

PY - 2011/11

Y1 - 2011/11

N2 - Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

AB - Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84873021372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873021372&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 963

EP - 972

JO - Molekulyarnaya Biologiya

JF - Molekulyarnaya Biologiya

SN - 0026-8984

IS - 6

ER -